HER2 mutations were found more commonly in HER2 + cancers with increasing lines of HER2 directed therapy (p = 0.04, Fig. 3c), suggesting acquisition of HER2 mutations as a mechanism of resistance to prior HER2 targeted therapies, and identifying a potential novel treatment strategy for HER2 + resistant disease. The gene discussed is ERBB2; the disease is cancer.